Riyadh, (UNA-OIC) – Saudi Arabia’s Ministry of Health announced the implementation of phase III efficacy trials of a vaccine against the coronavirus on Saturday.
The trials will be conducted within the framework of the cooperation agreement between the Kingdom and China that includes the implementation of clinical trials.
The Ministry of Health indicated that an action plan is being developed to implement the phase III of the clinical trial of the vaccine against coronavirus in cooperation with the Chinese company CanSino, which has developed a vaccine against the virus and has carried out first and second phases trials in China.
The Ministry stated that the third phase will include multi-center clinical studies in different countries and large numbers of people after the vaccine’s effectiveness and safety has been confirmed following the first and second phases trials.
The study, which will be implemented in the Kingdom of Saudi Arabia, targets at least 5,000 healthy volunteers over the age of 18.
The Ministry of Health pointed out that work is currently underway to prepare screening and testing centers while also making preparations to start the procedures in three main cities: Riyadh, Dammam, and Makkah.
This step comes as a continuation of the studies and research being conducted by the Ministry of Health in this area, as it, in cooperation with the World Health Organization (WHO), recently conducted an advanced multi-center clinical study in seven hospitals inside the Kingdom to combat the novel coronavirus pandemic.
The Ministry confirmed its continuous efforts to address the COVID-19 pandemic and the search for an effective vaccine with unlimited support from the government of the Custodian of the Two Holy Mosques King Salman and the Crown Prince, which has spared no effort to preserve the health and safety of its citizens and residents.